Wealth Enhancement Advisory Services LLC Acquires 8,793 Shares of The Clorox Company (NYSE:CLX)

Wealth Enhancement Advisory Services LLC increased its holdings in shares of The Clorox Company (NYSE:CLX - Free Report) by 17.9% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 57,934 shares of the company's stock after acquiring an additional 8,793 shares during the period. Wealth Enhancement Advisory Services LLC's holdings in Clorox were worth $8,531,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of the company. Azzad Asset Management Inc. ADV bought a new position in Clorox in the 1st quarter valued at $2,901,000. Stanley Laman Group Ltd. bought a new position in Clorox in the 1st quarter valued at $202,000. Everhart Financial Group Inc. boosted its position in Clorox by 6.4% in the 1st quarter. Everhart Financial Group Inc. now owns 2,718 shares of the company's stock valued at $400,000 after buying an additional 163 shares during the last quarter. Donald L. Hagan LLC boosted its position in Clorox by 2.8% in the 1st quarter. Donald L. Hagan LLC now owns 10,477 shares of the company's stock valued at $1,543,000 after buying an additional 287 shares during the last quarter. Finally, NorthCrest Asset Manangement LLC boosted its position in Clorox by 67.9% in the 1st quarter. NorthCrest Asset Manangement LLC now owns 3,535 shares of the company's stock valued at $521,000 after buying an additional 1,430 shares during the last quarter. 78.53% of the stock is currently owned by institutional investors.

Insider Activity at Clorox

In related news, Director Pierre R. Breber bought 4,000 shares of the stock in a transaction that occurred on Wednesday, May 7th. The shares were acquired at an average price of $136.57 per share, with a total value of $546,280.00. Following the completion of the transaction, the director now owns 4,000 shares in the company, valued at $546,280. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 0.57% of the stock is owned by company insiders.

Clorox Stock Performance

CLX opened at $122.33 on Tuesday. The business's 50-day moving average price is $132.74 and its two-hundred day moving average price is $146.30. The Clorox Company has a 1 year low of $120.33 and a 1 year high of $171.37. The company has a market capitalization of $15.08 billion, a price-to-earnings ratio of 21.96, a P/E/G ratio of 2.73 and a beta of 0.54. The company has a debt-to-equity ratio of 13.07, a current ratio of 0.74 and a quick ratio of 0.44.

Clorox (NYSE:CLX - Get Free Report) last released its quarterly earnings results on Monday, May 5th. The company reported $1.45 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.57 by ($0.12). The firm had revenue of $1.67 billion during the quarter, compared to analyst estimates of $1.74 billion. Clorox had a net margin of 9.89% and a return on equity of 324.23%. The business's revenue for the quarter was down 8.0% compared to the same quarter last year. During the same period in the prior year, the business earned $1.71 EPS. Equities analysts expect that The Clorox Company will post 7.15 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have commented on the company. JPMorgan Chase & Co. decreased their price objective on Clorox from $151.00 to $144.00 and set a "neutral" rating on the stock in a research report on Tuesday, May 6th. UBS Group reduced their price target on Clorox from $176.00 to $154.00 and set a "neutral" rating on the stock in a research report on Thursday, April 17th. Morgan Stanley reduced their price target on Clorox from $165.00 to $150.00 and set an "equal weight" rating on the stock in a research report on Tuesday, May 6th. Barclays reduced their price target on Clorox from $134.00 to $129.00 and set an "underweight" rating on the stock in a research report on Wednesday, May 7th. Finally, Citigroup reduced their price target on Clorox from $165.00 to $150.00 and set a "neutral" rating on the stock in a research report on Monday, April 14th. Three investment analysts have rated the stock with a sell rating, ten have given a hold rating and one has assigned a buy rating to the stock. According to MarketBeat, the company presently has an average rating of "Hold" and an average target price of $151.23.

Clorox Company Profile

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.